Secukinumab
- Generic Name
- Secukinumab
- Brand Names
- Cosentyx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1229022-83-6
- Unique Ingredient Identifier
- DLG4EML025
- Background
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Fo...
- Indication
Secukinumab is indicated the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy. In Europe, the drug is used in children and adolescents six to 18 years of age for this indication.
...
- Associated Conditions
- Enthesitis Related Arthritis (ERA), Juvenile Idiopathic Arthritis (JIA), Juvenile psoriatic arthritis, Non-radiographic Axial Spondyloarthritis, Severe Plaque psoriasis, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Plaque psoriasis
- Associated Therapies
- -
Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)
- Conditions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05583604
Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT05569174
- Locations
- 🇩🇪
Novartis Investigative Site, Schoenebeck, Germany
Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1518
- Registration Number
- NCT05513014
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17743
- Registration Number
- NCT05320159
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT05232864
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, VNM, Vietnam
COVID-19 VaccinE Response in Rheumatology Patients
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Jeffrey Curtis
- Target Recruit Count
- 1000
- Registration Number
- NCT05080218
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States
🇺🇸University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1002
- Registration Number
- NCT04894890
- Locations
- 🇨🇳
Novartis Investigative Site, Zhejiang, China
EBIO - Enthesitis Biopsy Study
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 10
- Registration Number
- NCT04887597
- Locations
- 🇩🇪
University Hospital Erlangen, Department of Internal Medicine 3, Rheumatology and Immunology, Erlangen, Bavaria, Germany
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT04737330
- Locations
- 🇩🇪
Novartis Investigative Site, Mainz, Germany
Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 138
- Registration Number
- NCT04732117
- Locations
- 🇨🇳
Novartis Investigative Site, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.